Please find Investor Presentation on UFR for Q1FY2027.

GPT Healthcare Limited Regd. Office: GPT Centre, JC-25, Sector III, Salt Lake, Kolkata – 700 106, India CIN : L70101WB1989PLC047402 Phone : +91-33-4050-7000, Email : info@gptgroup.co.in , Visit us: www.gptgroup.co.in GPTHEALTH/CS/SE/2026-27 August 3, 2026 The Department of Corporate Services National Stock Exchange of India Limited BSE Limited, Exchange Plaza, Plot no. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (E), Dalal Street Mumbai - 400 051 Mumbai – 400001 Scrip Symbol: GPTHEALTH Scrip Code: 544131 ISIN: INE486R01017 Dear Sir/Madam Sub: Submission of Investor Presentation on Un-Audited Financial Results for the 1st quarter ended on June 30, 2026: In compliance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith a copy of Investor Presentation on the Un-Audited Financial Results for the 1st quarter ended on June 30, 2026 for dissemination to general public and Investors. Kindly take the aforesaid information on record and oblige. Thanking You, Yours sincerely, For GPT Healthcare Limited Ankur Sharma Company Secretary and Compliance Officer M. No A31833 Encl. As Above. GGPPTT HHEEAALLTTHHCCAARREE LLIIMMIITTEEDD Investor Presentation Q1FY27 Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by GPT Healthcare Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contractor binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guaranteeing of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. Key Highlights of the Q1FY27 Operational performance remained healthy, with ARPOB increasing to ₹42350 driven by an improved clinical mix and operating efficiencies. Network occupancy stood at 45.5% (excluding Raipur: 58.07%), while mature hospitals continued to deliver resilient performance supported by steady patient footfalls and strong community trust. Salt Lake strengthened its leadership in robotic-assisted surgery with over 800+ cumulative procedures, while Dum Dum remained the highest-occupied hospital in the network, supported by its established renal transplant programme with more than 700+ transplants completed. Agartala expanded its oncology platform with PET Scan and Linear Accelerator facilities, completing over 700+ radiation therapy procedures, while Howrah has launched MAKO robotic knee replacement surgeries, supporting higher realisations and improved patient outcomes. Raipur continued to ramp up high-acuity specialties, including oncology, cardiology and transplant services, and remains on track to achieve operational breakeven by Q3 FY27. The overall strategy is focused on maintaining network occupancy at around 70%, improving ARPOB through a higher share of complex and high-acuity procedures, expanding capacity to over 1,000 beds over the next two years, and sustaining long-term ROCE of approximately 25% through disciplined expansion and efficient asset utilisation. Company Overview GPT Healthcare Limited is a fast-growing hospital platform in Eastern India, operating five, neighborhood tertiary-care hospitals located within densely populated residential areas. 719 115 Beds- total capacity Full time consultants Designed around a proximity-based model, its hospitals offer the reassurance of advanced medical care almost at the doorstep—ensuring high accessibility for patients while enabling strong control over clinical quality, operating standards, and long-term returns on capital. 800+ Led by Dr. Om Tantia, the company follows a disciplined, 630 Robot-enabled Surgeries capital-efficient operating model with advanced capabilities Visiting consultants across oncology, cardiology, renal transplants, and robotic surgeries. With a clearly defined plan to scale to a 1,000-bed network by FY2027, supported by integrated diagnostics and a strong regional brand, GPT Healthcare is well positioned to capture NABH & NABL Optimally sized rising healthcare demand, enhance profitability, and deliver accreditations Hospitals sustained value to investors. Financial Snapshot Financial Snapshot for Q1 FY27 Q1 FY27 Revenue from Operations EBITDA & EBITDA Margin PAT & PAT Margin Rs 126.2 Cr Rs 26.2 Cr Rs 12.7 Cr (Overall – 20.4% Margin, (9.9 % Margin) Raipur – Rs 10.6 Cr, Mature – Rs 115.6 Cr 38.5% YoY) 65.7% YoY 17.8% YoY ARPOB Occupancy Rate % Dum Dum Rs 42,350 45.5 % Raipur – 17.4%, Mature – 58.07% Agartala FY26 Salt lake Howrah Jamshedpur Revenue from Operations EBITDA & EBITDA Margin PAT & PAT Margin Rs 42.2 Cr Rs 478.5 Cr Rs 90.1 Cr Raipur (8.82% Margin) Raipur – Rs 28 Cr, Mature – Rs 450.5 Cr (Overall - 18.84% Margin, -(15.43%) YoY 15.14% YoY -(1.86%) YoY Existing hospitals Upcoming Hospitals Salt lake Jamshedpur ARPOB Occupancy Rate % Dum Dum Howrah Rs.39,243 45.87% Agartala Other proposed Raipur – 12.35, Mature – 55.90% Raipur Hospitals *planned hospital 6 ARPOB- Average Rate Per Occupied bed ; ALOS- Average length of stay Hospital-wise performance for Q1 FY27 Salt lake Hospital Agartala Hospital Dum-Dum Hospital Howrah Hospital Raipur Hospital West Bengal Tripura West Bengal West Bengal Chhattisgarh Year of 2000 2011 2013 2019 2025 commissioning Q1FY27 Q1FY27 Q1FY27 Q1FY27 Q1FY27 Bed capacity 85 205 155 116 158 (No of beds) Revenue (INR Cr) 21.8 35.2 39.7 18.8 10.6 Occupancy Rate (%) 62.4% 45.3% 65.4% 45.2% 17.4% ARPOB (INR) 45,282 41,573 43,041 39,435 42,320 Hospital Portfolio ILS Salt Lake Hospital 85-bed tertiary surgical hospital with 17 ICUs and 3 OTs, scaled from an 8-bed facility. 85 17 & 3 Clinical focus on robotic gastro and bariatric surgeries, enabling higher case complexity. Total Number of beds ICU & OTS Specialised care offerings including diabetic foot care [Showing first 8,000 characters — download PDF for full document]